Screener
Axsome Therapeutics AXSM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(64,542) | $(59,413) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 23,438 | 23,308 |
| Amortization of intangible asset | 1,572 | 1,572 |
| Amortization of debt discount | 159 | 667 |
| Depreciation | 116 | 149 |
| Loss in fair value of contingent consideration | 590 | 1,512 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's stock-based comp?
- Axsome Therapeutics (AXSM) reported stock-based comp of $23.44M in Q1 2026.
- How has Axsome Therapeutics's stock-based comp changed year-over-year?
- Axsome Therapeutics's stock-based comp increased by 0.6% year-over-year, from $23.31M to $23.44M.
- What is the long-term trend for Axsome Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Axsome Therapeutics's stock-based comp has grown at a 45.7% compound annual growth rate (CAGR), from $20.8M to $93.75M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Axsome Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude